share_log

HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $50 Price Target

Benzinga ·  Mar 19 12:24

HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment